The company is also initiating a post-approval clinical study of Orthovisc mini to gain additional clinical experience with regional opinion leaders who specialize in the treatment of osteoarthritis in small joints.
Charles Sherwood, Anika’s president and CEO, said: “We will utilize our existing European Orthovisc distribution network for this new product, and anticipate filling initial orders before the end of the first quarter of 2008.”